Literature DB >> 9477926

Plasma cortisol concentrations preceding lactate-induced panic. Psychological, biochemical, and physiological correlates.

J D Coplan1, R Goetz, D F Klein, L A Papp, A J Fyer, M R Liebowitz, S O Davies, J M Gorman.   

Abstract

BACKGROUND: We evaluated the role of plasma cortisol levels in determining sodium lactate-induced panic by reporting psychological, physiological, and biochemical data collected from an extended sample of 214 subjects during the "placebo" infusion (isotonic saline solution) immediately preceding the lactate infusion procedure.
METHODS: One hundred seventy patients with panic disorder, 101 (59%) of whom were assessed to have panicked (P group), and 69 (41%) who were assessed not to have panicked (NP group) with lactate infusion; and 44 normal healthy volunteer controls (1 of whom panicked with lactate infusion) were studied.
RESULTS: Before the lactate infusion, the P group exhibited hypothalamic-pituitary-adrenal (HPA) axis activation (high plasma cortisol levels) and evidence of hyperventilation (low PCO2 levels) in comparison with NP and control groups. Self-reported fear, dyspnea, and diastolic blood pressure were highest in the P group, intermediate in the NP group, and lowest in the control group. Within the P group, baseline fear scores correlated inversely with PCO2 levels and positively with cortisol levels while PCO2 levels correlated negatively with cortisol levels. Significant predictors of lactate-induced panic were prelactate infusion fear and the interaction of high cortisol levels and low PCO2 levels.
CONCLUSION: Combined data suggest that synchronized elevations of HPA axis activity, self-reported fear, and hyperventilation during the period before lactate infusion predisposes to lactate-induced panic.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9477926     DOI: 10.1001/archpsyc.55.2.130

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  7 in total

Review 1.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

Review 2.  Hyperventilation in panic disorder and asthma: empirical evidence and clinical strategies.

Authors:  Alicia E Meuret; Thomas Ritz
Journal:  Int J Psychophysiol       Date:  2010-05-25       Impact factor: 2.997

Review 3.  Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety.

Authors:  Michael Davis; David L Walker; Leigh Miles; Christian Grillon
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

4.  Chronic inhibition of GABA synthesis in the bed nucleus of the stria terminalis elicits anxiety-like behavior.

Authors:  Tj Sajdyk; Pl Johnson; Sd Fitz; A Shekhar
Journal:  J Psychopharmacol       Date:  2008-02-28       Impact factor: 4.153

Review 5.  Models and mechanisms of anxiety: evidence from startle studies.

Authors:  Christian Grillon
Journal:  Psychopharmacology (Berl)       Date:  2007-12-06       Impact factor: 4.530

6.  Lifestyle Behaviours Add to the Armoury of Treatment Options for Panic Disorder: An Evidence-Based Reasoning.

Authors:  Rod Lambert
Journal:  Int J Environ Res Public Health       Date:  2015-06-18       Impact factor: 3.390

7.  Cortisol awakening response in drug-naïve panic disorder.

Authors:  Katarzyna Jakuszkowiak-Wojten; Jerzy Landowski; Mariusz S Wiglusz; Wiesław Jerzy Cubała
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-27       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.